Liftstream is an executive search recruitment company in the life sciences sector
Dr Karl-Ludwig Kley – Merck KGaA – Executive Leadership Series
Authored by James Sheppard
Posted in Pharmaceutical business
Tagged 13 for 13, AZ Electronics, BeiGene, BioRN, CEO, clinical trials, Erbitux, executive, INSPIRE, Karl-Ludwig Kley, Liftstream, Merck KGaA, Merck Serono, restructuring, Stimuvax
Leave a comment
Symphogen’s Monoclonal Antibody Technology Making Waves
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, antibody drug conjugate, clinical trials, conjugated mAb, epidermal growth factor receptor, Essex Woodland, European Society of Hematology, Genentech, hematology, Kirsten Drejer, Medicon Valley, Merck, monoclonal antibody, Novo A/S, oncology, Phase II, PKA, Roche, squamous cell carcinoma of the head & neck, SYM004, Symphogen
Leave a comment
Swedish Pharmalink receives Orphan Drug Approval for Busulipo
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Busulipo, cancer, clinical studies, clinical trials, EMA, FDA, funding, gold standard, hematopoietic stem cell transplantation, HSCT, Investinor, Johan Häggblad, Karolinska Institute, Medicon Valley, Nefecon, oncology, Orphan Drug, pharmacokinetics, Pharmalink Ab, primary IgA nephropathy, series C, sweden, venture capital
Leave a comment
Ipsen secures development platform with Syntaxin Purchase
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abbingworth, Agromegaly, Allergan, biopharmaceutical, biotechnology, Botox, chronic pain, clinical trials, Dr John Craddock, Dr Keith Foster, Ipsen, J&J Development, Lundbeckfond Ventures, Marc de Garidel, neurology, Oxford Biotech, peptides, platforms, SROne, SXN101959, Syntaxin, toxins
Leave a comment
Johnson & Johnson grows prostate cancer franchise with Aragon purchase
Authored by James Sheppard
Adaptive Clinical Trials in Orphan Drug Development
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases
Tagged Adaptive clinical trials, adaptive design, Aptiv Solutions, biotech, biotechnology, clinical development, clinical trials, DMD, Duchenne Muscular Dystrophy, EMA, FDA, GSK, NewLink Genetics, Novartis, Orphan drugs, Parent Project MD, Pulmatrix, rare diseases, venture capital
Leave a comment